Filing Details
- Accession Number:
- 0001127602-25-009283
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-03-12 18:41:26
- Reporting Period:
- 2025-03-10
- Filing Date:
- 2025-03-12
- Accepted Time:
- 2025-03-12 18:41:26
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
882095 | Gilead Sciences Inc. | GILD | Biological Products, (No Disgnostic Substances) (2836) | 943047598 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1310204 | D Andrew Dickinson | Gilead Sciences, Inc. 333 Lakeside Drive Foster City CA 94404 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2025-03-10 | 4,916 | $63.91 | 173,977 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2025-03-10 | 13,013 | $63.91 | 186,990 | No | 4 | M | Direct | |
Common Stock | Disposition | 2025-03-10 | 4,916 | $117.30 | 182,074 | No | 4 | S | Direct | |
Common Stock | Disposition | 2025-03-10 | 13,013 | $118.50 | 169,061 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2025-03-10 | 7,968 | $0.00 | 177,029 | No | 4 | M | Direct | |
Common Stock | Disposition | 2025-03-10 | 3,855 | $117.21 | 173,174 | No | 4 | F | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | F | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Non-qualified Stock Option (Right to Buy) | Disposition | 2025-03-10 | 4,916 | $0.00 | 4,916 | $63.91 |
Common Stock | Non-qualified Stock Option (Right to Buy) | Disposition | 2025-03-10 | 13,013 | $0.00 | 13,013 | $63.91 |
Common Stock | Restricted Stock Unit | Disposition | 2025-03-10 | 7,968 | $0.00 | 7,968 | $0.00 |
Common Stock | Non-qualified Stock Option (Right to Buy) | Acquisiton | 2025-03-10 | 49,020 | $0.00 | 49,020 | $117.21 |
Common Stock | Restricted Stock Unit | Acquisiton | 2025-03-10 | 11,090 | $0.00 | 11,090 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
13,013 | 2031-03-10 | No | 4 | M | Direct | |
0 | 2031-03-10 | No | 4 | M | Direct | |
27,519 | No | 4 | M | Direct | ||
49,020 | 2035-03-10 | No | 4 | A | Direct | |
38,609 | No | 4 | A | Direct |
Footnotes
- The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.
- Sale prices reported for the transactions reported here range from $116.97 to $117.88. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- Sale prices reported for the transactions reported here range from $118.00 to $118.80. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
- The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
- The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.